Early real-world data from numerous US centers demonstrate strong anti-inflammatory efficacy and safety of dexamethasone intraocular suspension 9% (DEXYCU, EyePoint Pharmaceuticals) comparable to controlled clinical trials, according to data reported at AAO 2020 Virtual.
The researchers set out to characterize early real-world experiences with dexamethasone intraocular suspension 9% using data from a large group of patients and study sites. Data were collected from records of patients who received dexamethasone intraocular suspension 9% after cataract surgery between March 12 and December 15, 2019. Use of additional perioperative anti-inflammatory drugs was done at the discretion of each individual surgeon. Rate of anterior chamber cell (ACC) and flare (ACF) cleaning and mean IOP were included in the study.
In total, 483 eyes of 381 patients were treated with dexamethasone intraocular suspension. Among those with records at postop Days 1, 8, 14, and 30, 44%, 65%, 86%, and 90% of eyes had no anterior chamber cells. At these visits, 85%, 97%, 98%, and 98% of eyes had no flare. Target visual acuity was achieved in 96% of eyes. Mean (SD) IOP at postop Days 1, 8, 14, and 30 was 18.2 (6.23), 15.4 (4.15), 15.3 (3.58), and 14.2 (3.64) mm Hg. Results from the retrospective study, including adverse events, were similar to those from the controlled, phase 3 clinical studies.
Weinstock RJ, et al. Dexamethasone intraocular suspension 9% after cataract surgery: data from a retrospective study. Presented at: AAO 2020 Virtual. [Session: PO050].